[144] MaxCyte, Inc. SEC Filing

Rhea-AI Filing Summary

MaxCyte, Inc. (MXCT) has filed a Form 144 indicating a proposed resale of 10,684 shares of common stock on or about 25 June 2025. The shares will be sold through Stifel Nicolaus & Company on the Nasdaq market. At the filing date, MaxCyte had 106,318,532 shares outstanding, so the proposed sale represents roughly 0.01% of total shares, limiting potential dilution or market impact. The aggregate market value of the block is stated at $22,378, implying a reference price of approximately $2.09 per share.

The seller acquired the securities on 11 June 2025 via Restricted Stock Units (RSUs) and paid for the shares in cash on the same date. No prior sales were reported during the last three months, and the form contains no remarks suggesting unusual circumstances. While the filing confirms the transaction is being made under Rule 144 and that the seller attests to possessing no undisclosed material adverse information, several identification fields (issuer address, filer name, relationship to issuer) were left blank, providing limited context on the insider’s position.

Positive

• Sale size is immaterial at roughly 0.01% of shares outstanding, implying minimal dilution and market impact.
• Seller attests to possessing no undisclosed negative information, reducing informational asymmetry concerns.

Negative

• Insider disposition can signal reduced confidence, even if small in magnitude.
• Key filer details missing—name and relationship to issuer—limit investors’ ability to gauge significance of the transaction.

Insights

Securities Analyst

TL;DR: Small Rule 144 sale (0.01% float) by unidentified holder; negligible dilution, mildly negative sentiment.

The Form 144 covers 10,684 MaxCyte shares worth about $22k. With 106.3 million shares outstanding, the sale equates to roughly 0.01% of the float—far below any level that would pressure liquidity or alter ownership structure. Nonetheless, insider-initiated disposals can weigh on sentiment, especially when coming shortly after RSU vesting (acquired 11 June 2025, sale planned 25 June 2025). Lack of filer identity and role obscures whether this is a senior executive or a rank-and-file employee, diluting interpretive value. Overall, the filing is routine and immaterial to valuation.

Corporate Governance Expert

TL;DR: Routine disclosure; incomplete filer details limit governance insight, but no red flags detected.

Rule 144 filings are standard for insiders liquidating restricted securities. The absence of name, relationship, and contact data is unusual but not a violation; the SEC still accepts partially redacted submissions. Because no other sales occurred in the past three months and the seller explicitly certifies having no undisclosed adverse information, compliance risk appears low. The modest trade size suggests it is likely a liquidity event rather than a strategic exit. Governance watchers should monitor subsequent Form 4s to confirm execution and identify the insider class involved.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	10684	22378.00	106318532	06/25/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/11/2025	Restricted Stock Units	Issuer			21367	06/11/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many MaxCyte (MXCT) shares are being sold under this Form 144?

The filing covers 10,684 common shares to be sold on Nasdaq.

What percentage of MaxCyte’s outstanding shares does this sale represent?

Approximately 0.01% of the 106,318,532 shares outstanding.

When were the shares acquired and how?

The seller acquired the shares on 11 June 2025 via Restricted Stock Units and paid cash for them the same day.

What is the aggregate market value of the proposed sale?

The aggregate value stated is $22,378.

Who is the broker handling the transaction?

The broker is Stifel Nicolaus & Company Inc.